Navigation Links
Soligenix Announces Expansion of Partnership With Sigma-Tau Pharmaceuticals for orBec® in Europe
Date:7/28/2011

er clinical trial conducted at the Fred Hutchinson Cancer Research Center, which demonstrated statistical significance in its primary endpoint of controlling GI GVHD (p-value 0.02). The second study was a 129-patient pivotal Phase 3 multi-center clinical trial conducted at 16 leading bone marrow/stem cell transplant centers in the US and France. Although orBec® did not achieve statistical significance in the primary endpoint of its pivotal trial, namely median time-to-treatment failure through Day 50 (p-value 0.1177), orBec® did achieve statistical significance in other key secondary endpoints such as the proportion of patients free of GVHD at Day 50 (p-value 0.05) and Day 80 (p-value 0.005) and the median time to treatment failure through Day 80 (p-value 0.0226), as well as a 66% reduction in mortality among patients randomized to orBec® at 200 days post-transplant with only 5 patient (8%) deaths in the orBec® group compared to 16 patient (24%) deaths in the placebo group (p-value 0.0139).  At one year post-randomization in the Phase 3 trial, 18 patients (29%) in the orBec® group and 28 patients (42%) in the placebo group died within one year of randomization (46% reduction in mortality, p-value 0.04).

orBec® represents a first-of-its-kind oral, locally acting therapy tailored to treat the GI manifestation of acute GVHD, the organ system where GVHD is most frequently encountered and highly problematic.  orBec® is intended to reduce the need for systemic immunosuppressive drugs to treat GI GVHD.  orBec® is formulated for oral administration in GVHD patients as a single product consisting of two tablets; one tablet is intended to release BDP in the proximal portions of the GI tract, and the other tablet is intended to release BDP in the distal portions of the GI tract.  Oral BDP may also have application in treating other GI disorders characterized by severe inflammation.  

In addition to
'/>"/>

SOURCE Soligenix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Soligenix Announces Appointment of Jerome Zeldis, MD, PhD and Keith Brownlie, CPA to its Board of Directors
2. Soligenix Appoints Joseph Warusz as Vice President of Administration and Controller
3. Soligenix to Present at 13th Annual BIO CEO & Investor Conference
4. Soligenix Appoints Kevin Horgan, MD, as Chief Medical Officer
5. Soligenix Executes Exclusive License with the University of Colorado for Vaccine Thermostabilization Technology
6. Soligenix Announces Positive Preliminary Results of SGX202 in Radiation Injury
7. Soligenix Announces Preliminary Results of its Phase 2 Clinical Trial of orBec® in the Prevention of Acute GVHD
8. Soligenix to Present at the Rodman & Renshaw Healthcare Conference on September 15, 2010 at 10AM EDT
9. Soligenix Announces Award of $1.2 Million FDA Orphan Products Development Grant
10. Soligenix to Present at the OneMedForum Conference on Wednesday, June 30 at 2PM EDT
11. Soligenix Announces Publication of Positive Data Describing Protection from Mucosal and Systemic Ricin Intoxication by Intradermal RiVax™ Administration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... , Jan. 22, 2015  ViewRay™, a privately held ... into an exclusive distributor agreement with ITOCHU Corporation (Tokyo ... therapy system for the treatment of cancer in ... system, is the world,s first and only MRI-guided radiation ...
(Date:1/22/2015)... , Jan. 22, 2015 /PRNewswire/ - Pivotal Therapeutics Inc. (OTCQX:PVTTF; ... a focus on Omega-3 therapies for cardiovascular disease and overall ... the Company,s accomplishments in 2014 and its outlook for 2015 ... Dear Fellow Shareholders, We would like to take ...
(Date:1/22/2015)... Jan. 22, 2015 Increasing sophistication among enterprise buyers ... localization purchasing in 2015, says Moravia CMO, ... recent study by market research firm Common Sense Advisory, ... for their translation and localization needs. "From a language ...
Breaking Medicine Technology:ITOCHU Named the Exclusive Distributor for ViewRay's MRI-Guided Radiation Therapy System in Japan 2Pivotal Therapeutics: Year in Review and CEO Update 2Pivotal Therapeutics: Year in Review and CEO Update 3Pivotal Therapeutics: Year in Review and CEO Update 4Pivotal Therapeutics: Year in Review and CEO Update 5Pivotal Therapeutics: Year in Review and CEO Update 6Pivotal Therapeutics: Year in Review and CEO Update 7Moravia Sees Single-Sourcing as Key Localization Trend in 2015 2
... continuance needed to reduce cardiovascular,risks, ROCHESTER, Minn., ... therapy for enlarged prostates experience significant,surges in blood ... heart attack or,stroke, according to new research findings ... Clinic-led study of 185 consecutive patients who received,transurethral ...
... designed to validate drug targets for the fatal,neurodegenerative ... April 8, 2008 The ALS,Therapy Development Institute ... agreement with the Allen Institute for Brain Science ... using diseased tissues from a,preclinical animal model of ...
Cached Medicine Technology:Microwave Treatments for Enlarged Prostate Cause Blood Pressure Surges 2Microwave Treatments for Enlarged Prostate Cause Blood Pressure Surges 3ALS Therapy Development Institute Signs Collaboration Agreement with the Allen Institute for Brain Science 2ALS Therapy Development Institute Signs Collaboration Agreement with the Allen Institute for Brain Science 3
(Date:1/22/2015)... Angelweddingdress is a famous wedding dress company offering many trendy ... on Facebook, Twitter, and Pinterest. The fans will have an ... lottery every week. , Moreover, the company has extended its ... Angelweddingdress homepage for more information. , Angelweddingdress is ...
(Date:1/22/2015)... New York (PRWEB) January 22, 2015 The ... ) in the U.S. District Court, Southern District of West ... Bard, Inc. in that proceeding’s first bellwether trial. In an ... for a new trial after finding that C.R. Bard had ...
(Date:1/22/2015)... New York (PRWEB) January 22, 2015 ... after Fresenius Medical Care recalled its GranuFlo and NaturaLyte ... multidistrict litigation underway in U.S. District Court, District of ... dated January 20th, the Court has remanded a case ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Carinsurancesavings.biz has released ... accidental death and dismemberment insurance . , Purchasing an ... can be very advantageous. This type of rider provides benefits ... dismemberment can be considered a lesser form of life insurance. ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Yesterday, ... Bonilla (D-Concord) and Kristin Olsen (R-Modesto) were honored ... leadership in advancing biotechnology, biomedical science, medical device ... Olsen each received the “2014 Life Sciences Champion” ...
Breaking Medicine News(10 mins):Health News:Angelweddingdress Invites Its Customers To Follow It On Facebook, Twitter, And Pinterest 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 3Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 4Health News:Accidental Death and Dismemberment Insurance Can Be Purchased at Low Prices Online 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 3
... two sets of brothers with autism, Johns Hopkins scientists ... to be linked very specifically to the severity of ... interacting protein 1), is a blueprint for a traffic-directing ... brain cells across which chemical signals flow. ...
... A study led by researchers at the University of Michigan ... drug compounds they developed shrank tumors, with few side effects. ... cancer, looked at two compounds designed to activate a protein ... a significant number of human cancers. In some cases, it ...
... Machinery (ACM) has named Takeo Kanade, the U.A. and ... at Carnegie Mellon University, the 2010 winner of the ... computer vision and robotics. , The Newell Award, named ... School of Computer Science, recognizes career contributions that have ...
... cancer is the second most common cancer among women, with ... estrogen over a long period of time is one factor ... One way a woman can combat this risk factor ... with the activity of estrogen. Now, researchers at Fox ...
... Reporter , TUESDAY, April 5 (HealthDay News) -- In ... study, researchers report that risks to postmenopausal women who ... ended the treatment. The study found that ... and blood clots, which were elevated while they were ...
... April 6 (HealthDay News) -- Poor overall health seems ... survivors, according to the results of a new study. ... breast cancer survivors participating in the After Breast Cancer ... shortly after diagnosis, and follow-up occurred an average of ...
Cached Medicine News:Health News:Gene linked to severity of autism's social dysfunction 2Health News:Gene linked to severity of autism's social dysfunction 3Health News:CMU's Takeo Kanade wins ACM/AAAI Award for career contributions to computer vision, robotics 2Health News:Fox Chase researchers find that fish oil boosts responses to breast cancer drug tamoxifen 2Health News:Risks of Estrogen Hormone Therapy Seen to Fade After Treatment Ends 2Health News:Risks of Estrogen Hormone Therapy Seen to Fade After Treatment Ends 3Health News:Overall Health May Be Key to Beating Breast Cancer 2
... Operation: , Standby: All toggle switches at off ... pulse/s); 10 s (1 pulses/10 s) , Tetanus: ... pulses/s) , Train-Of-Four: Single (4 pulses/2 s); repeat ... Output Current: Adjustable from 0-70 mA(HI range) 0-6.0mA ...
... of Operation: , Double Burst : 2 60-ms bursts ... 1 s (1 pulse/s) , Tetanus: 50 Hz ... Train-Of-Four: Single (4 pulses/2 s) , Output Current: Adjustable ... Monophasic pulses (200-us duration) , Indicators: Battery LED (green) ...
... Modes of Operation: , Standby: A standby ... stimulus pulses. , Twitch: 1 s (1 pulse/s) ... Train-Of-Four: Single (4 pulses/2 s) , Output Current: ... Square Wave Monophasic pulses (200-us duration) , Indicators: ...
Anesthesia Associates Model 100 Compact Peripheral Nerve Stimulator, incorporates the latest state-of-the-art electronics with solid state cicuitry to ensure trouble-free operation and extended batte...
Medicine Products: